抗心绞痛药的药物相互作用

摘要/Abstract

摘要： 心绞痛是常见的心血管疾病。临床常用的抗心绞痛药易发生药物之间的相互作用。本文综述了与常用抗心绞痛药物相关的药动学方面的相互作用研究进展, 为临床用药提供参考。

Abstract: Angina pectoris is the major clinical symptom of myocardial ischemia. Angina pectoris can be managed by using drugs that either improve perfusion of the myocardium or reduce its metabolic demand. Many of the drugs used in angina pectoris are the substrate of cytochrome P450, drug interactions are easily to occur when antianginal drugs co-administrated with other drugs and foods. In this article, the drug interaction of main antianginal drugs in pharmacokinetics were reviewed, and it will help the rational use of antianginal drugs in clinical medication.

Key words: antianginal drugs, drug interaction, pharmacokinetics, cytochrome P450

中图分类号:

李筱旻, 郭歆, 程泽能. 抗心绞痛药的药物相互作用[J]. 中国临床药理学与治疗学, 2007, 12(5): 493-498.

LI Xiao-min, GUO Xin, CHENG Ze-neng. Drug interactions with antianginal drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(5): 493-498.

参考文献

1 赵梦华.硝酸酯类药物治疗稳定型心绞痛的研究现状[J].医学综述, 1999;5:237-238.
2 李必祥.基层医院应重视地高辛与其它药物的相互作用[J].现代临床医学, 2006;32:300.
3 Bolanowski J, Kobusiak-Prokopowicz M, Wegrzyn B.Interactions between propranolol, isosorbide and nitroglycerin[J].Pol Tyg Lek, 1992 ;47:1141-1142.
4 张涛.长期大量饮酒对药效的影响[J].中国社区医师( 综合版) , 2006;9:11.
5 Ishikura F, Beppu S, Hamada T, et al.Effects of sildenafil citrate( Viagra) combined with nitrate on the heart[J].Circulation,2000;102:2516.
6 Bednarcyzk EM, Furniss SM, Green JA, et al.Evaluation of the indomethacin-nitroglycerin interaction with positron-emission tomography[J].J Cardiovasc Pharmacol, 1997;30:731-733.
7 Harder S, Thurmann P.Clinically important drug interactions with anticoagulants.An update [J].Clin Pharmacokinet, 1996 ;30:416-444.
8 Harder S, Klinkhardt U.Thrombolytics:drug interactions of clinical significance[J].Drug Saf, 2000;23:391-399.
9 潘云, 曹善萍.卡托普利与其他药物的相互作用[J].中国民康医学, 2006;18:545-546.
10 周茂金, 梅任奎, 苏美英.影响地高辛血药浓度的药物[J].华西药学杂志, 1994;9:111-114.
11 李静, 钱莉, 吕迁洲.与细胞色素P450 酶系介导相关的常用心血管药物相互作用[J].中国药房, 2006;17:1179-1181.
12 Kovarik JM, Beyer D, Bizot MN, et al.Pharmacokinetic interaction between verapamil and everolimus in healthy subjects[J].Br J Clin Pharmacol, 2005;60:434-437.
13 Kovarik JM, Beyer D, Schmouder RL.Everolimus drug interactions: application of a classification system for clinical decision making[J].Biopharm Drug Dispos, 2006;27:421-426.
14 Jacobson TA.Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors[J].Am J Cardiol, 2004 ;94:1140-1146.
15 Lamberg TS, Kivisto KT, Neuvonen PJ.Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone[J].Clin Pharmacol Ther, 1998;63:640-645.
16 黄林清, 周世文, 周素琴, 等.维拉帕米对硫唑嘌呤代谢物6-巯嘌呤药动学的影响[J].华西药学杂志, 2001 ;16:31-33.
17 Bailey DG, Dresser GK.Interactions between grapefruit juice and cardiovascular drugs[J].Am J Cardiovasc Drugs, 2004 ;4:281-297.
18 诸敏, 姚彤炜, 曾苏.银杏黄酮的体外葡醛酸反应及其药物相互作用[J].浙江大学学报( 医学版) , 2004 ;33:15-20.
19 Grundy JS, Foster RT.The nifedipine gastrointestinal therapeutic system ( GITS).Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties[J].Clin Pharmacokinet,1996;30:28-51.
20 史文石, 邢凤玲, 李宝清.西咪替丁与配伍用药物的相互作用[J].中国医药导报, 2006 ;3:96-97.
21 Nishio S, Watanabe H, Kosuge K.Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension[J].Hypertens Res, 2005 ;28:223-227.
22 Glesby MJ, Aberg JA, Kendall MA.Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers[J].Clin Pharmacol Ther, 2005;78:143-153.
23 Varhe A, Olkkola KT, Neuvonen PJ.Diltiazem enhances the effects of triazolam by inhibiting its metabolism[J].Clin Pharmacol Ther, 1996 ;59:369-375.
24 Sawada T, Sako K, Yoshihara K, et al.Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam[J].J Pharm Sci, 2003;92:790-797.
25 Kazuhiro K, Yang J, HiroshiW, et al.Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status[J].Drug Metab Dispos, 2001;29:1284-1289.
26 Azie NE, Brater DC, Becker PA, et al.The interaction of diltiazem with lovastatin and pravastatin[J].Clin Pharmacol Ther, 1998 ;64:369-377.
27 Choi JS, Piao YJ, Han HK.Pharmacokinetic interaction between fluvastatin and diltiazem in rats[J].Biopharm Drug Dispos, 2006;27:437-441.
28 Christensen H, Asberg A, Holmboe AB, et al.Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers[J].Eur J Clin Pharmacol, 2002;58:515-520.
29 Bottiger Y, Sawe J, Brattstrom C, et al.Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers[J].Clin Pharmacol Ther, 2001 ;69:32-40.
30 Alderman CP, Hundertmark JD, Soetratma TW.Interaction of serotonin re-uptake inhibitors with perhexiline[J].Aust N Z J Psychiatry , 1997;31:601-603.
31 Saranteas T, Mourouzis C, Koumoura F, et al.Effects of propranolol or paracetamol on lidocaine concentrations in serum and tissues[J].J Oral Maxillofac Surg , 2003;61:604-607.
32 Vercruysse I, Massart DL, Dupont AG.Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol[J].Eur J Clin Pharmacol, 1995 ;49:121-125.
33 戈升荣, 施安国, 王平全.尼索地平包衣片与某些药物的相互作用[J].中国医院药学杂志, 2000 ;20:675-676.
34 Goldberg MR, Sciberras D, De Smet MD, et al.Influence ofβ-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B 1D agonist:differential effects of propranolol, nadolol and metoprolol[J].Br J Clin Pharmacol, 2001;52:69-76.
35 Rolan P.Potential drug interactions with the novel antimigraine compound zolmitriptan ( Zomig, 311C90) [J].Cephalalgia,1997 ;17:21-27.
36 Bauer LA, Horn JR, Maxon MS, et al.Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition[J].J Clin Pharmacol, 2000;40:533-543.
37 曲福军, 张雪娟, 宋力, 等.美多洛尔与卡托普利在健康人体内的药代动力学相互作用[J].中国药学杂志,2001 ;36:111-113.
38 Hemeryck A, Lefebvre RA, De Vriendt C, et al.Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers[J].Clin Pharmacol Ther, 2000;67:283-291.
39 朱立勤, 娄建石.细胞色素P450 与药物代谢的研究现状[J].中国临床药理学与治疗学, 2004;9:1081-1086.
40 Somer M, Kallio J, Pesonen U, et al.Influence of hydroxychloroquine on the bioavailability of oral metoprolol[J].Br J Clin Pharmacol, 2000;49:549-554.
41 Hamelin BA, Bouayad A, Methot J, et al.Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity[J].Clin Pharmacol Ther, 2000;67:466-477.
42 Sharma A, Pibarot P, Pilote S, et al.Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women[J].J Pharmacol Exp Ther, 2005 ;313:1172-1181.
43 Werner U, Werner D, Rau T, et al.Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans[J].Clin Pharmacol Ther, 2003;74:130-137.
44 Lilja JJ, Raaska K, Neuvonen PJ.Effects of orange juice on the pharmacokinetics of atenolol[J].Eur J Clin Pharmacol, 2005;61:337-340.
45 黄佳.抗凝药物的相互作用与合理用药[J].继续医学教育, 2006 ;20:30-33.
46 Verstuyft C, Strabach S, El-Morabet H, et al.Dipyridamole enhances digoxin bioavailability via P-gly coprotein inhibition[J].Clin Pharmacol Ther, 2003 ;73:51-60.
47 Babaoglu MO, Karadag O, Saikawa Y, et al.Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole:a case report[J].Eur J Clin Pharmacol, 2004;60:455-456.
48 De La Cruz JP, Blanco E, Sanchez de la Cuesta F.Effect of dipyridamole and aspirin on the platelet-neutrophil interaction via the nitric oxide pathway[J].Eur J Pharmacol, 2000;397: 35-41.

[1]	武玉洁, 赵程程, 席庆. 蒙特卡洛模拟评价替加环素治疗革兰阴性菌感染给药方案[J]. 中国临床药理学与治疗学, 2023, 28(9): 1027-1033.
[2]	何雪茹, 李颖, 马银玲, 付裕豪, 荀雪姣, 董占军. 索拉非尼和达格列净在大鼠体中药代动力学相互作用研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 498-507.
[3]	黄志伟, 李熠, 徐晓勇, 张蕾, 沈一峰, 李华芳. 五种群体药动学分析工具计算结果的比较[J]. 中国临床药理学与治疗学, 2023, 28(5): 525-535.
[4]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[5]	燕强勇, 向大雄, 朱荣华, 杨玲凤, 阳喜定, 李晶晶, 范晓, 刘赛, 熊守军, 方平飞. 盐酸西那卡塞片在中国健康人群的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 171-177.
[6]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[7]	李雪静, 江金平, 李思凝, 万林飞, 周响响, 杨梿, 兰轲. 一项在中国精神分裂症受试者中评估氯氮平片的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1121-1130.
[8]	何雪茹, 付裕豪, 荀雪姣, 崔艳军, 董占军. 尿苷二磷酸葡醛酸转移酶介导的酪氨酸激酶抑制剂药物相互作用研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 936-945.
[9]	张进华, 刘茂柏, 蔡铭智, 郑英丽, 劳海燕, 向倩, 都丽萍, 朱珠, 董婧, 左笑丛, 李新刚, 尚德为, 陈冰, 叶岩荣, 王玉珠, 高建军, 张健, 陈万生, 谢海棠, 焦正. 模型引导的华法林精准用药：中国专家共识（2022版）[J]. 中国临床药理学与治疗学, 2022, 27(11): 1201-1212.
[10]	贾元威, 沈杰, 储冀汝, 张翠锋, 谢海棠, 杨斌, 李相鸿, 郑丹丹, 赵静惠. 豆腐果苷及其代谢产物时辰药动学研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 986-994.
[11]	刘璐, 陈笑艳. 国产小分子化学创新药临床药物相互作用研究现状[J]. 中国临床药理学与治疗学, 2021, 26(8): 863-875.
[12]	孟强, 刘克辛. 转运体介导药物相互作用的研究现状及展望[J]. 中国临床药理学与治疗学, 2021, 26(8): 876-888.
[13]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[14]	吴懿, 方芳, 陈瑛, 樊军卫. 供受体CYP3A5基因型对肝移植术后早期他克莫司谷浓度的影响作用及其临床意义[J]. 中国临床药理学与治疗学, 2021, 26(6): 631-639.
[15]	徐国防, 高盼, 刘平, 赖耀文, 李广辉, 赵岳, 张永玲, 李晓苏, 齐琦. 肿瘤患者个体差异对卡培他滨药物代谢动力学影响[J]. 中国临床药理学与治疗学, 2021, 26(3): 305-311.